Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World
Hugo Jourdain1, Nicolas Albin2,3, Adrien Monard2,3
1EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance, Saint-Denis, France.
Introduction:
Trastuzumab deruxtecan (T-DXd) has been approved for human epidermal growth factor receptor 2-positive locally advanced or metastatic gastric and gastroesophageal junction (HER2+ mG/GEJ) cancer since July 2022 in France, through an accelerated approval. The aim of this study was to evaluate its real-world use.
Methods:
We characterized T-DXd users treated for HER2+ mG/GEJ cancer using data from the French National Health Insurance database.
Results:
The cohort included 196 patients, mostly men (78.1%), with a median age of 65 years. Median overall survival reached 7.7 months (95% CI: 6.2-9.0).
Discussion:
Patients treated with T-DXd for HER2+ mG/GEJ cancer in the real world showed lower outcomes than those in pivotal clinical trials, consistent with previous reports on accelerated approvals.
